Will German Epilepsy Patients Have Access To Fycompa Once Again?

After deciding to withdraw Fycompa from the market last year, rather than sell it at Germany’s HTA agency approved price, Eisai’s epilepsy drug, Fycompa could be re-entered onto the market. Read more here. (Source: PMLiVE, 2/11/14).

You might also be interested in:

HTA in Europe: Key Success Factors for Positive HTA Recommendations June 21, 2018
Report: Times Vary Widely on Reimbursement Decisions for New… October 21, 2018
ICER Using New Economic Modeling Platform for Value Assessment August 24, 2018
Time to Market: Accelerating Market Access January 4, 2019
Time, Hope Dwindle for ALS Patients as Radicava Stays Out of… May 27, 2018
Once-Free Drug to Cost $300,000-plus Per Year February 13, 2019
Drug’s $375K Price Tag Leads to Rationing, Criticism February 21, 2019